Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer - a phase II trial

被引：10

作者：

Bernardi, D

Talamini, R

Zanetti, M

Simonelli, C

Vaccher, E

Spina, M

Tirelli, U

机构：

[1] IRCCS, Ctr Riferimento Oncol, Div Med Oncol A, I-33081 Aviano, PN, Italy

[2] Ctr Riferimento Oncol, Epidemiol Unit, I-33081 Aviano, PN, Italy

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2004年 / 7卷 / 01期

关键词：

chemotherapy; hormone resistance; mitoxantrone; prostate cancer; vinorelbine;

D O I：

10.1038/sj.pcan.4500685

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A total of 28 patients were treated with mitoxantrone, vinorelbine and prednisone every 3 weeks. In all, 11 patients (46%) had a significant prostate-specific antigen decline for a median duration of 11.4 months. Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom. Median duration of the response was 9.5 months. A confirmed partial response was obtained in three out of seven patients who had bidimensionally measurable disease. Toxicity was manageable. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic harmonoresistant prostate cancer, promoting the exploration of new regimens containing antimicrotubule agents in addition to mitoxantrone-prednisone.

引用

页码：45 / 49

页数：5

共 31 条

[1] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].

Bubley, GJ ;

Carducci, M ;

Dahut, W ;

Dawson, N ;

Daliani, D ;

Eisenberger, M ;

Figg, WD ;

Freidlin, B ;

Halabi, S ;

Hudes, G ;

Hussain, M ;

Kaplan, R ;

Myers, C ;

Oh, W ;

Petrylak, DP ;

Reed, E ;

Roth, B ;

Sartor, O ;

Scher, H ;

Simons, J ;

Sinibaldi, V ;

Small, EJ ;

Smith, MR ;

Trump, DL ;

Vollmer, R ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467

[2] Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer [J].

Colleoni, M ;

Graiff, C ;

Vicario, G ;

Nelli, P ;

Sgarbossa, G ;

Pancheri, F ;

Manente, P .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (04) :383-386

[3] Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress? [J].

Culine, S ;

Droz, JP .

ANNALS OF ONCOLOGY, 2000, 11 (12) :1523-1530

[4]

Dawson NA, 1999, SEMIN ONCOL, V26, P174

[5] A PHASE-II STUDY OF NAVELBINE (VINORELBINE) IN THE TREATMENT OF NON SMALL-CELL LUNG-CANCER [J].

DEPIERRE, A ;

LEMARIE, E ;

DABOUIS, G ;

GARNIER, G ;

JACOULET, P ;

DALPHIN, JC .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (02) :115-119

[6]

EISENBERGER M A, 1988, NCI (National Cancer Institute) Monographs, P151

[7] Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial [J].

Fields-Jones, S ;

Koletsky, A ;

Wilding, G ;

O'Rourke, M ;

O'Rourke, T ;

Eckardt, J ;

Yates, B ;

McGuirt, C ;

Burris, HA .

ANNALS OF ONCOLOGY, 1999, 10 (11) :1307-1310

[8]

Goktas S, 1999, SEMIN ONCOL, V26, P162

[9] METHODS FOR MEASURING CLINICAL PAIN IN HUMANS [J].

HOUDE, RW .

ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1982, 26 :25-29

[10] Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer [J].

Hudes, GR ;

Nathan, F ;

Khater, C ;

Haas, N ;

Cornfield, M ;

Giantonio, B ;

Greenberg, R ;

Gomella, L ;

Litwin, S ;

Ross, E ;

Roethke, S ;

McAleer, C .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3156-3163

← 1 2 3 4 →